Momentus and Orbit Fab Partner to Advance Space Servicing with Podracer and RAFTI Demonstration Flight
Fueling the future of space—Momentus and Orbit Fab demonstrates next-gen refueling and sensing technologies—delivering agile operations and mission resilience in orbit.
Funded by the U.S. Air Force Research Laboratory (AFRL), Podracer will conduct a flight demonstration of infrared imaging sensors, image processing technology, and a control module to enhance space domain awareness aboard the Vigoride 7 orbital service vehicle (OSV). Podracer will also be used as part of a rendezvous and proximity operations (RPO) demonstration mission that Momentus plans to conduct during the Vigoride 7 mission using a system developed by Momentus.
Through Vigoride's communications and data transfer systems, Orbit Fab will operate the Podracer payload remotely from its Mission Operations Center in Colorado, ensuring real-time control and monitoring of the hosted payload mission.
During the Vigoride 7 mission, Momentus and Orbit Fab plan to conduct the first flight demonstration of a hydrazine compatible, Space Systems Command approved RAFTI. Orbit Fab's advanced refueling interface is designed to extend the operational lifespan of satellites, by enabling spacecraft docking and refueling, thereby eliminating the current limitations imposed by onboard fuel reserves. This advancement is expected to significantly reduce costs and improve operational flexibility for satellite operators by mitigating mission constraints caused by fuel shortages.
'We are thrilled to collaborate with Orbit Fab to demonstrate the Podracer and RAFTI payloads to continue to push the boundaries of what's possible in space servicing and space domain awareness,' said Momentus CEO John Rood. 'The new contract with Orbit Fab adds another advanced technology payload to what will be an exciting mission early next year in which Momentus will support several cutting-edge payloads from the U.S. Defense Advanced Research Projects Agency, AFRL, and innovative early-stage space companies.'
"We're excited to be working with Momentus as we advance the future of in-space mobility and dynamic space operations,' said Dr. Melissa Sampson, Vice President of Business Development, at Orbit Fab. 'Our collaboration underscores the critical role of on-orbit refueling for increasing satellite maneuverability and mission life. Together, we're pushing the boundaries of space technology and enabling a more agile and sustainable infrastructure in orbit.'
This launch marks Momentus' fourth Vigoride mission and its first collaboration with Orbit Fab. In addition to Podracer, Momentus will provide transportation and hosted payload support during the Vigoride 7 mission for several additional commercial and U.S. government customers, including the U.S. Defense Department.
As demand for Vigoride missions continues to grow, Momentus is actively planning a follow up mission using its Vigoride 8 OSV. Government and commercial customers interested in launching microsatellites up to 200 kg, cubesats, and hosted payloads in LEO are encouraged to contact the Momentus Commercial Team at sales@momentusspace.com for booking opportunities while space remains available.
About Momentus
Momentus is a U.S. commercial space company offering satellites, satellite components, and in-space transportation and infrastructure services. The Company offers satellites to support government and commercial customers for missions like communications, missile tracking, and cutting-edge science missions. Momentus offers services such as hosted payloads, support for in-space assembly, on-orbit servicing and refueling, and transportation of satellites to specific orbits.
Forward-Looking Statements
This press release contains certain statements which may constitute 'forward-looking statements' for purposes of the federal securities laws. Forward-looking statements include, but are not limited to, statements regarding the expected filing of the Company's Form 10-K and Form 10-Q and its management team's expectations, hopes, beliefs, intentions or strategies regarding the future, projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, and are not guarantees of future performance. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Momentus' control. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to risks and uncertainties included under the heading 'Risk Factors' in the Annual Report on Form 10-K filed by the Company on April 9, 2025, as such factors may be updated from time to time in our other filings with the Commission, accessible on the Commission's website at www.sec.gov and the Investor Relations section of our website at investors.momentus.space. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and, except as required by law, the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
TeraWulf Launches $400 Million Convertible Notes Offering To Fund Data Center Expansion
TeraWulf (NASDAQ:WULF), an operator of vertically integrated, predominantly zero-carbon digital infrastructure, launched a private offering of $400 million aggregate principal amount of convertible senior notes due 2031. The company may also grant initial purchasers a 13-day option to buy up to an additional $60 million of notes. TeraWulf plans to use the proceeds primarily to fund capped call transactions to reduce dilution from potential note will allocate the remaining proceeds toward expanding its data centers and supporting general corporate purposes. The notes will be senior unsecured obligations, paying semiannual interest starting March 1, 2026, and maturing September 1, 2031. Regarding pricing, TeraWulf expects to enter into capped call transactions with financial institutions to mitigate dilution from potential conversions. Separately, TeraWulf announced that Fluidstack has expanded its footprint at the Lake Mariner data center campus in Western New York. The expansion introduces CB-5, a new purpose-built data center that will add 160 MW of critical IT load when operations begin in the second half of 2026. As part of the CB-5 lease, Alphabet's (NASDAQ:GOOGL) (NASDAQ:GOOG) Google committed an additional $1.4 billion to backstop project-related debt financing and secured warrants to purchase 32.5 million TeraWulf shares. This new commitment raises Google's total backstop to $3.2 billion and expands its pro forma equity stake in TeraWulf to about 14%. The CB-5 lease mirrors the economics of Fluidstack's earlier CB-3 and CB-4 agreements, ensuring consistent terms across the Lake Mariner buildout. With CB-5, TeraWulf boosts Fluidstack's total contracted capacity to approximately 360 MW, making Lake Mariner one of the largest high-performance computing campuses in the United States. TeraWulf and Fluidstack are also discussing further expansions to meet growing AI demand. TeraWulf stock has gained close to 59% year-to-date and over 78% in the last five days upon the Google deal. TeraWulf shares extended their rally last Friday after the company cemented a landmark deal, strengthening its role in artificial intelligence infrastructure. The stock jumped more than 40% in last Thursday's midday trading and has climbed 78% since Monday's open. On Thursday, TeraWulf signed two 10-year high-performance computing (HPC) colocation agreements with Fluidstack, locking in approximately $3.7 billion in contracted revenue. Under the agreements, TeraWulf will supply more than 200 MW of power from its Lake Mariner data center in New York, with extension options that could lift the contract's total value to $8.7 billion. Google fueled momentum by backing $1.8 billion of Fluidstack's lease obligations and securing warrants for an 8% equity stake in TeraWulf. The announcement followed a stronger-than-expected quarterly report. TeraWulf reported a second-quarter loss of 5 cents per share, beating the 7-cent loss forecast. Sales reached $47.64 million, above the $46.08 million estimate. CEO Paul Prager also pointed to integrating Beowulf Electricity & Data to streamline operations and cut costs. Price Action: WULF stock is trading lower by 4.01% to $8.620 premarket at last check Monday. Photo by Gorodenkoff via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article TeraWulf Launches $400 Million Convertible Notes Offering To Fund Data Center Expansion originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
Chicago Tribune
14 minutes ago
- Chicago Tribune
Wall Street is quiet in premarket trading ahead of Trump's meeting with Ukraine's Zelenskyy
Wall Street ticked modestly lower early Monday ahead of U.S. President Donald Trump's meeting later Monday with Ukrainian President Volodymyr Zelenskyy and other European leaders. Futures for the S&P 500, Dow Jones Industrial Average and Nasdaq were all 0.1% lower before the bell. Markets showed scant reaction to Trump's inconclusive summit meeting with Russian President Vladimir Putin on Friday. Investors are also watching for cues from an annual meeting in Jackson Hole, Wyoming, of top central bankers later this week. In premarket trading, Soho House jumped 16% after the global membership-based club said it was being taken private by hotel operator MCR. Executive Chairman Ron Burkle and other big shareholders will retain their equity interests and control of the business. Dayforce, a human resources software company, climbed more than 28% before the bell on media reports that it is being acquired by Chicago-based private equity firm Thoma Bravo. Bloomberg reported that Thoma Bravo was offering $9 billion, including debt, to take Dayforce private. Some of the biggest U.S. retailers will report their latest financial results throughout the week, including Home Depot, Target and Walmart. Trump's meeting with Zelenskyy will include other European leaders who were not included in the president's talks in Anchorage, Alaska, with Putin. The European allies are seeking to present a united front in safeguarding Ukraine and the continent from any widening aggression from Moscow. An annual meeting in Jackson Hole, Wyoming, of top central bankers later this week will be watched closely for hints about possible interest rate cuts from Federal Reserve chair Jerome Powell. He is due to speak Friday at the conference. 'While the official theme is labor markets, investors will scrutinize any hint of September policy direction, especially after last week's mixed inflation data,' Ipek Ozkardeskaya of Swissquote said in a commentary, adding that 'any progress on Ukraine peace talks could push global equities higher still.' Expectations have been building that the Fed will cut interest rates at its next meeting in September, though mixed reports on the U.S. economy have undercut those bets somewhat. At midday in Europe, Germany's DAX lost 0.3%, while the CAC 40 in Paris dropped 0.7%. Britain's FTSE 100 was flat. In Asia, Japan's Nikkei 225 picked up 0.8%, while the Hang Seng in Hong Kong gave up early gains, losing 0.4%. The Shanghai Composite index jumped 1%. It's trading near it's highest level in a decade. Australia's S&P/ASX 200 picked up 0.2%. The Kospi in South Korea declined 1.5% on heavy selling of semiconductor makers like Samsung Electronics, whose shares fell 2.2%. SK Hynix lost 3.3% as investors fretted over the possibility of more U.S. tariffs on computer chips.
Yahoo
29 minutes ago
- Yahoo
Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis
- In the overall modified intention-to-treat (mITT) population, improvements across all efficacy and secondary endpoints, including 24% reduction in knee pain and 26% improvement in knee function, were observed in the AllocetraTM treatment arm vs placebo; moreover, 72% reduction in knee pain and 95% improvement in knee function were observed for age-related primary osteoarthritis patients compared with placebo – a substantial, clinically meaningful and statistically significant effect in commonly used Phase III primary endpoints for knee osteoarthritis clinical trials. - Favorable safety profile – No severe adverse events; limited, typically mild to moderate, transient, and treatable side effects occurred in most patients treated with Allocetra™ - Webinar today at 8:00 a.m. Eastern Time Nes-Ziona, Israel, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the 'Company'), a clinical-stage macrophage reprogramming immunotherapy company, today announced positive three-month topline data from the Phase IIa stage of ENX-CL-05-001, a multi-center, two-stage Phase I/II double-blind, randomized, placebo-controlled clinical trial evaluating Allocetra™ in patients with moderate-to-severe knee osteoarthritis. Oren Hershkovitz, Ph.D, CEO of Enlivex, commented, 'We are excited to share the topline three-month data from ENX-CL-05-001. We believe these results provide clear indication that Allocetra™ has the potential to become a novel, safe and effective treatment for knee osteoarthritis, a growing market with significant unmet medical need.' The Company will host a webinar today at 8:00 am Eastern Time to provide in-depth analysis of the results. To join the webinar, please click To join the webinar, please register at: It is suggested participants join the webinar at least 15 minutes prior to the scheduled start time to avoid any delays in attendance. About ENX-CL-05-001ENX-CL-05-001 is a multi-center Phase I/II clinical trial consisting of two stages. The first stage was a Phase I safety run-in, open-label dose escalation phase to characterize the safety and tolerability of Allocetra™ injections to the target knee, in order to identify the dose and injection regimen for the subsequent Phase IIa stage. The Phase IIa stage is a double-blind, randomized, placebo-controlled multi-centered trial. In addition to evaluating safety, the study protocol was designed to efficiently find a strong signal in a responder population to guide future development, and includes an interim statistical evaluation, conducted by an independent third party and blinded to the Company, to assess the potential value of enrollment of up to 50 patients in addition to the original randomized sample size of 130, and its marginal impact on the p-value of the statistical estimation of the total group and specifically to identify a potential responder sub-group. The trial's key efficacy endpoints evaluate joint-pain and joint-function in comparison to placebo at three months, six months and 12 months post treatment. ABOUT KNEE OSTEOARTHRITIS Osteoarthritis is by far the most common form of arthritis, affecting more than 32.5 million Americans and more than 300 million individuals worldwide. About half of knees with ACL injuries develop osteoarthritis within 5 to 15 years. 78 million Americans are projected to have osteoarthritis by the year 2040. Symptomatic knee osteoarthritis is particularly prevalent and disabling, with 40% of men and 47% of women developing knee osteoarthritis in their lifetimes. Osteoarthritis accounts for over one million hospitalizations annually in the United States, primarily for total joint replacement. The burden of osteoarthritis is enormous, and the need for treatments that reduce pain and attendant disability for persons with osteoarthritis is critical. There are currently no medications approved by either the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) that have been demonstrated to arrest, slow or reverse progression of structural damage in the joint. ABOUT ENLIVEX Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening and life debilitating conditions. For more information, visit Safe Harbor Statement: This press release contains forward-looking statements, which may be identified by words such as 'expects,' 'plans,' 'projects,' 'will,' 'may,' 'anticipates,' 'believes,' 'should,' 'would,' 'could,' 'intends,' 'estimates,' 'suggests,' 'target,' 'has the potential to' and other words of similar meaning, including statements regarding expected cash balances, expected clinical trial results, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRATM programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex's business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRATM product line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivex's filings with the Securities and Exchange Commission, including in the Company's most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law. ENLIVEX CONTACT Shachar Shlosberger, CFOEnlivex Therapeutics, INVESTOR RELATIONS CONTACT Dave Gentry, CEORedChip Companies Inc.1-407-644-4256ENLV@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
